글로벌 발작성 야간혈색소뇨증 약물 시장 - 2029년까지의 산업 동향 및 예측

시장 분석 및 통찰력 글로벌 발작성 야간 혈색소뇨증 약물 시장

발작성 야간 혈색소뇨증 약물 시장은 2022-2029년 예측 기간에 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 위에서 언급한 예측 기간에 12.31%의 CAGR로 성장할 것으로 예측되는 시장을 분석합니다. 규제 기관의 특별 지정 증가와 정교한 의료 인프라의 존재는 시장 성장을 강화하는 요인입니다.

발작성 야간 혈색소뇨증은 적혈구의 조기 분해(용혈)를 유발하는 희귀 혈액 질환입니다. 이 질환은 신체의 면역 체계가 적혈구를 공격하고 보호하는 단백질이 부족하여 적혈구를 파괴할 때 발생합니다. 소변에 진한 붉은색 또는 밝은 붉은색 혈액, 빈혈, 정맥 내 혈액 응고, 두통, 피로, 호흡 곤란, 창백한 노란색 피부는 모두 이 질환의 증상입니다.

글로벌 발작성 야간 혈색소뇨증(PNH) 치료제 시장은 미국 식품의약국(FDA)의 발작성 야간 혈색소뇨증(PNH) 치료 승인이 증가함에 따라 예측 기간 동안 상당히 성장할 것으로 예상됩니다. 여기에는 철분 보충제, 수혈, 혈액 응고 방지제, 에쿨리주맙(솔리리스), 골수 이식이 포함됩니다. 또한, 비용 효율적인 발작성 야간 혈색소뇨증(PNH) 치료법을 개발하기 위한 새로운 연구 및 개발 연구가 진행 중이며, 이는 발작성 야간 혈색소뇨증 치료제 시장의 수익을 견인할 것으로 예상됩니다.

혈액 질환의 유병률이 증가함에 따라 시장이 앞으로 나아가고 있습니다. 용혈성 결함이나 비정상적인 조혈 줄기 세포의 원인을 표적으로 삼는 생물학적 제제의 등장은 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 개발도상국의 충족되지 않은 높은 약물 수요도 시장 성장을 촉진하고 있습니다. 정부, 공공 및 민간 기관의 신약 개발에 대한 투자 증가가 시장 성장을 촉진하고 있습니다.

However, the high cost of therapy and surgical procedures, such as stem cell transplants (SCT), is limiting market growth. Adverse side effects of available treatments may impede market growth during the forecast period. The market's growth is being hampered by an unfavourable reimbursement environment in developing regions. The risks associated with bone marrow transplantation are impeding market growth

This paroxysmal nocturnal hemoglobinuria drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the paroxysmal nocturnal hemoglobinuria drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Scope and Market Size

Paroxysmal nocturnal hemoglobinuria drug market is segmented of the basis of treatment, drugs, route of administration, distribution channel and end user. The growth among these specific segments will help users analyze niche pockets of growth and strategies to approach the market and determine your core application areas and difference in your target markets.

• Based on treatment, the paroxysmal nocturnal hemoglobinuria drug market is segmented as medication, supplements, blood transfusion, and bone marrow transplant
• Based on drugs, the paroxysmal nocturnal hemoglobinuria drug market is segmented as eculizumab, ravulizumab and others
• Based on the route of administration, the paroxysmal nocturnal hemoglobinuria drug market is segmented into oral and parenteral
• Based on the distribution channel, the paroxysmal nocturnal hemoglobinuria drug market is segmented as direct, online pharmacy, retailers and others
• Based on end user, the paroxysmal nocturnal hemoglobinuria drug market is segmented into hospitals, homecare, specialty clinics and others

Paroxysmal Nocturnal Hemoglobinuria Drug Market Country Level Analysis

Paroxysmal nocturnal hemoglobinuria drug market is analyzed and market size information is provided by the country, treatment, drugs, route of administration, distribution channel and end user as referenced above.

The countries covered in the paroxysmal nocturnal hemoglobinuria drug market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the paroxysmal nocturnal hemoglobinuria drug market due to the presence of major key players, increasing the penetration of episodic treatments and the increase of immunoglobulin reimbursement in the U. S., as well as the growth of the aging population. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector as well as rising low cost treatment and medical tourism for treatment of paroxysmal nocturnal hemoglobinuria.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Paroxysmal nocturnal hemoglobinuria drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to paroxysmal nocturnal hemoglobinuria (PNH) market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the paroxysmal nocturnal hemoglobinuria (PNH) market in the growth period.

Competitive Landscape and Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis

발작성 야간 혈색소뇨증 약물 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 임상 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 발작성 야간 혈색소뇨증 약물 시장 조사와 관련된 회사의 초점에만 관련이 있습니다.

발작성 야간혈색소뇨증 약물 시장의 주요 기업으로는 Alexion Pharmaceuticals, Inc, Akari Therapeutics, Plc, Apellis Pharmaceuticals, CinnaGen Co, Ra Pharmaceuticals, Inc, Amgen Inc, Alnylam Pharmaceuticals, Inc, Achillion Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals, Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, NorthStar Rx LLC, Abbott, Cook 및 Par Pharmaceutical 등이 있습니다.

SKU-50503